Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Beijing Changping Technology Innodevelop Group China

Beijing Changping Science and Technology Park Development Co., Ltd.(Chang Development) is an industrial ecological investment and operation platform wholly-owned by the Beijing Changping District Government. Prosperity Development has three business systems under its jurisdiction: asset management, technology finance, and industrial services. Focusing on the core elements of enterprise development, it provides a one-stop overall solution that integrates customized industrial space, industrial investment and financing, and in-depth industrial services. Fully activate innovative energy and help enterprises grow throughout the cycle.
Website:
http://www.bc-tid.com/
Partnering Objectives
Headquartner in China
Yes
佳 黄
国际项目合作总监 

BGI Group China

Founded in 1999, BGI is one of the world's leading life science and genomics organizations.
Website:
www.genomics.cn
Partnering Objectives
Headquartner in China
Yes
Jizhe Sun
Supervisor of the Board of Director’s Office 

bioBAY China

industrial park
Website:
www.biobay.com.cn
Partnering Objectives
Headquartner in China
Yes
lingling gao
investment manager 

BioChange Israel

BioChange is a biotech startup in tissue engineering and regenerative medicine. Our main product is a gelatin based injectable scaffold.

BioChange has developed CellFoam™ , a unique injectable cell adhesive-scaffold that stimulates guided tissue regeneration and supports cell seeding. When CellFoam is injected as stand alone, it completely degrades within the body after about 3 months of a remodeling phase, as new functional tissue is formed, replacing the aged or impaired tissue.

Our first human product is a therapy for skin ageing (BlueStim™ product), it modulates fibroblasts' behavior to regenerate new collagen, regaining skin thickness and quality. In other words, it turns aged skin to young.

The core technology can fit various applications in healthcare such as COPD, macular degeneration, neural repair, periodontal disease, and tissue bioprinting.
Website:
http://www.biochange.life/
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
Finding investors, technology partners and clients
Headquartner in China
No
Medtech Category
Mr. Ishay Attar
CEO 
Functionality
Management

Bioindustry Park Silvano Fumero Italy

Bioindustry Park “Silvano Fumero” is an Italian scientific and technological park, specialized in Life Sciences, located in the Piedmont region, near Turin. Bioindustry Park promotes and develops Life Sciences research and innovation by hosting and supporting companies, start-ups and research institutions. Bioindustry Park offers a full range of services aimed at the creation and development of life sciences and health care start-up and spin-off companies not only by providing laboratories and facilities, but also through valuable scientific and business support services. Bioindustry Park “Silvano Fumero” is also the managing company of bioPmed (http://www.biopmed.eu), the Piedmont health care innovation cluster that involves private and public actors in the pharmaceutical, biotech, medtech and eHealth sectors. BioPmed gathers about 100 companies, touching the whole value chain: from research and academic institutions and foundations, to start-ups, SMEs, private and public hospitals and health care centers.
Website:
https://www.bioindustrypark.eu/
Company Size (Fulltime employees)
11-50
Year of foundation
1998
Partnering Objectives
Please specify your partnering goal
Meet companies and investors in order to start new partnerships and activities (scouting and due diligences for investors, EU projects, international cooperation, licensing-out and promotion of our startups)
Headquartner in China
No
Biotech/Pharma Category
Dr. Arianna Floris
Life sciences Innovation Manager 
Functionality
Business Development

BioPegasus, LLC United States

BioPegasus, LLC specializes in a cost-effective and robust post-proteomics and post-protein and peptide array technology biomarker and target discovery technology platform. This proprietary platform is unique and transformative, allowing systematic, thorough and unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time. It aims to accelerate novel therapeutic and diagnostic development for some devastating diseases to improve our health and quality of life. These diseases include autoimmune diseases, cancer, and, in particular, Alzheimer’s disease.

BioPegasus' technology platform provides a revolutionary tool for systematical and thorough studying novel molecular interactions and mechanism of actions with any molecule of interest. The platform can be used to provide contract services with royalty payment potential to research institutions and companies in IVD, biotech and pharma sectors. The technology can also be packaged into commercial product(s) with a user manual for sale in the market world-wide.

BioPegasus currently is operated by its founder looking for an investor(s), partner(s), and sponsor(s)/client(s) or any form of collaboration/interest.

Website:
not available
Company Size (Fulltime employees)
1-10
Year of foundation
2006
Partnering Objectives
Please specify your partnering goal
1) Seeking investment(s) for developing cost-effective and minimally invasive blood antibody biomarker tests for Alzheimer’s disease diagnosis and early detection (a 3-year project); and/or 2) Looking for any interested party(ies) to work together.
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
biomarker and target discovery technology platform|||
Biotech/Pharma Asset Stage
Your Research Tool and Service name
A unique and transformative λ phage cDNA expression library construction and screening (not phage display). A cost-effective and robust novel biomarker and target discovery technology platform for novel diagnostic and therapeutic development.
Service Description
BioPegasus' technology platform provides a revolutionary tool for systematically and thoroughly studying novel molecular interactions and mechanism of actions with any molecule of interest and allowing unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time in novel diagnostic and therapeutic development.
Target client type
1) As diagnostic and early detection tests for Alzheimer's disease: general population for early detection (POCT, age 50 years and better) and patients for severity and diagnosis (lab tests); 2) As a research tool: client types include research institutions and diagnostic IVD, biotech and pharma companies
Slides Deck
(pdf, 957.61KB)
Dr. Tianlin Ma
Founder 
Functionality
Management

Bioprogress

Who We Are

An executive search and talent acquisition specialist with a wealth of experience in the life science business sector
An alternative to the generalist search firms that offer only general search services
Able to find the right talent for you with the right approach and understanding the complexity of the life science industry
Able to build pools helping our clients to attract a long term and sustainable talent pipeline for current and future requirements, placing your company ahead of competition

Website:
Www.Bioprogress.com
Partnering Objectives
Headquartner in China
No
Slides Deck
(pdf, 3.74MB)
Mr. Sam Meredith
Vice President 
Functionality
Management

Biostage, Inc. United States

Biostage is a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening conditions of the esophagus, bronchus and trachea.

The company’s novel Cellframe™ technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Our Cellframe technology is based on over 20 years of scientific progress in the fields of tissue engineering, cell biology and material science. Cellframe technology combines the best attributes of a synthetic scaffold with tissue engineering and cell biology to create what may be a revolutionary method of addressing organ damage.

Biostage has been developing its new generation of organ implants as a platform capable of being used in the esophagus and main airways (trachea and bronchi). The current platform, based on our Cellframe technology, represents a complete re-engineering of our earlier organ scaffold and cell technology to better stimulate the regenerative properties of each of these organs. Biostage’s Cellframe technology platform is used to create organ specific Cellspan implants. Recent large animal data showed promising results as our Cellframe technology applied to the esophagus achieved the regeneration of esophageal tissue.
Website:
www.biostage.com
Company Size (Fulltime employees)
11-50
Partnering Objectives
Please specify your partnering goal
Fund raising, invest,
Headquartner in China
No
Biotech/Pharma Category
Mr. Shunfu Hu
VP of Business Development and Operations 
Functionality
Business Development

BioValleyCHINA Ventures United States

Assist Consultation, Assistance, Service
• Identify Distribution Opportunities, Partners, Joint Ventures
• Guidance for Product Registration (SFDA), Regulatory Issues
• Intellectual Property Assessment
• Develop Successful Business Strategy
• Marketing/Analysis
• Manufacturing/Sourcing
• Investment Advisory

Website:
www.paulderiddermd.com
Year of foundation
2007
Partnering Objectives
Headquartner in China
No
Medtech Category
Medtech Development Stage
Paul DeRidder
President 
Functionality
Business Development

BirdoTech China

Shanghai based CRO and CDMO with offices in the US and Germany.
Website:
www.birdotech.com
Company Size (Fulltime employees)
501-1000
Year of foundation
2015
Partnering Objectives
Please specify your partnering goal
initiate research and manufacturing services
Headquartner in China
Yes
Your Research Tool and Service name
small molecules synthesis and manufacturing
Service Description
small molecules synthesis and manufacturing
Branden Lee
Dir. Business Development 
Functionality
Business Development